H. Ghesquières

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

H. Ghesquières, Marion Chevrier, Mouna Laadhari et al. · Annals of Oncology · 2019 · 237 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases

Carole Soussain, Sylvain Choquet, Emmanuelle Fourme et al. · Haematologica · 2012 · 108 citations · Full text

Medicine, Hematology, Oncology +15

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Aspasia Stamatoullas, H. Ghesquières, Lauriane Filliatre et al. · Blood · 2019 · 30 citations

Medicine, Oncology, Pharmacotherapy +15

EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL

Serge Bologna, Thierry Vander Borght, Josette Brière et al. · Hematological Oncology · 2021 · 24 citations · Full text

Medicine, Hematology, Oncology +13